SEARCH:   Advanced

Blood, 1 August 2007, Vol. 110, No. 3, pp. 847-850. Prepublished online as a Blood First Edition Paper on April 5, 2007; DOI 10.1182/blood-2007-01-067546. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2007-01-067546v1 110/3/847    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kordasti, S. Y. Articles by Mufti, G. J. Search for Related Content PubMed PubMed Citation Articles by Kordasti, S. Y. Articles by Mufti, G. J. Related Collections Hematopoiesis and Stem Cells Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Brief Report CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS) Shahram Y. Kordasti1, Wendy Ingram1, Janet Hayden1, David Darling1, Linda Barber1, Behdad Afzali2, Giovanna Lombardi2, Marcin W. Wlodarski3, Jaroslaw P. Maciejewski3, Farzin Farzaneh1, and Ghulam J. Mufti1 1 Department of Hematological Medicine, King's College London, London, United Kingdom; 2 Immunoregulation Laboratory, Department of Nephrology and Transplantation, King's College London, London, United Kingdom; 3 Experimental Hematology and Hematopoiesis Section, Cleveland Clinic Foundation, Cleveland, OH. Foxp3+ regulatory T cells (Tregs) play a central role in maintaining immune tolerance. A reduction in the function of Tregs is a key feature of autoimmune diseases, whereas their expansion in malignant diseases leads to the suppression of host antitumor responses. We analyzed the absolute number of CD4+ and CD8+ Tregs in the peripheral blood of 52 patients with myelodysplastic syndrome (MDS) and show a significant correlation between increased number of CD4+ Tregs and MDS subgroups with 5% or more bone marrow blasts (P < .001), high International Prognostic Scoring System (IPSS) score (P < .001), and disease progression (P < .001), whereas no correlation between CD8+ Tregs and prognostic variables was observed. The CD4+ Tregs showed a polyclonal spectratype, and the percentage of the naive subset was significantly higher in the high-risk patients compared with low-risk or healthy age-matched donors (P = .032). Our data suggest that CD4+ Treg expansion is a feature of high-risk MDS and progression to aggressive subtypes of the disease. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. Mittal, N. A. Marshall, L. Duncan, D. J. Culligan, R. N. Barker, and M. A. Vickers Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma Blood, June 1, 2008; 111(11): 5359 - 5370. [Abstract] [Full Text] [PDF] X. Feng, S. Kajigaya, E. E. Solomou, K. Keyvanfar, X. Xu, N. Raghavachari, P. J. Munson, T. M. Herndon, J. Chen, and N. S. Young Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro Blood, April 1, 2008; 111(7): 3675 - 3683. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020